Comparative evaluation of efficacy of multiple treatments in the treatment of vitiligo

Comparative evaluation of efficacy of dermabrasion alone, injection of melanocyte suspension and autologous melanocyte suspension transfer in the treatment of vitiligo

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138904081159N6

Enrollment

Registered

2013-08-25

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo. disorder of pigmentation

Interventions

Intervention 1: Dermabrasion alone: One time dermabrasion with cone shape head of high speed mini craft dermabrader until appearance of pinpoint bleeding in depigmented patch. Intervention 2: Combine

Dermabrasion alone: One time dermabrasion with cone shape head of high speed mini craft dermabrader until appearance of pinpoint bleeding in depigmented patch

Combined dermabrasion and melanocyte suspension in media: One time dermabrasion with cone shape head of high speed mini craft dermabrader until appearance of pinpoint bleeding in depigmented patch an

Injection of melanocyte suspension (only in phosphate-buffered saline (PBS)): One time 0.4 cc sub cutis injection of melanocyte suspension in phosphate-buffered saline with tenfold dilution

Combined dermabrasion and melanocyte suspension in PBS: One time dermabrasion with cone shape head of high speed mini craft dermabrader until appearance of pinpoint bleeding in depigmented patch and

Eligibility

Sex/Gender

All

Age

11 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1- Having no treatment within past 6 months 2- Men or women of 11-60 years old 3- Have a diagnosis of vitiligo with depigmented patch more than 5 cm despite receiving at least 3 months active treatment 4- Stable vitiligo for at least 1 year 5- No infection at recipient site 6- No history of keloid and or koebner phenomenon 7- No history of active hepatitis the B, C, or AIDS 8- No pregnancy or breast-feeding 9- No active uncontrolled chronic systemic disease Exclusion Criteria: Vitiligo patients with active or progressive disease within last 12 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pigmentation. Timepoint: Before intervention and 1 week, 3 weeks, 1 month and 3 months after transplantation. Method of measurement: Observation, wood lamp, visioface software.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFariba Jaffary

Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Ir

jaffary@pharm.mui.ac.ir+98 31 1337 3736

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026